Cara Therapeutics Appoints Mani Mohindru, Ph.D., Chief Financial Officer
August 01 2017 - 7:00AM
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company
focused on developing and commercializing new chemical entities
designed to alleviate pain and pruritus by selectively targeting
peripheral kappa opioid receptors, today announced the appointment
of Mani Mohindru, Ph.D., as Chief Financial Officer (CFO) and Chief
Strategy Officer, effective August 15, 2017. Josef Schoell, who has
held the CFO position at Cara for more than a decade, will be
retiring.
“We are very pleased to welcome Mani to the Cara
management team. She brings a wealth of strategic development and
financial expertise from her years of leadership in the biopharma
industry, which we look forward to drawing upon as we advance CR845
through late-stage clinical development and towards the
marketplace,” said Derek Chalmers, Ph.D., D.Sc., President and
Chief Executive Officer of Cara Therapeutics. “Our team
congratulates Josef and wishes him the very best in his retirement,
with gratitude for his many significant contributions over the
years.”
“I am thrilled to join Cara’s leadership team at
such an exciting time for the company,” said Dr. Mohindru. “CR845
has the potential to address a broad range of pain and pruritic
conditions with high unmet medical needs. I look forward to
executing on Cara’s plans to bring CR845 to patients while
continuing to drive shareholder value.”
Dr. Mohindru brings more than a decade of
leadership experience in the biopharmaceutical industry to Cara.
Most recently, she served as Chief Strategy Officer at Curis, Inc.
(Nasdaq:CRIS), where she was instrumental in the development and
management of overall corporate strategy. She was also
responsible for the company’s engagement with the investment
community, building extensive relationships with industry analysts
and investors. Earlier in her career, Dr. Mohindru spent several
years as an equity research analyst covering the biotechnology
sector at ThinkEquity, LLC, Credit Suisse and UBS. She also
co-founded Immtox LLC, a privately held biotechnology company, and
was a healthcare industry consultant at Axon Healthcare Partners
and SAI Healthcare (acquired by IMS Health). Dr. Mohindru received
her Ph.D. in neurosciences from Northwestern University.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage
biopharmaceutical company focused on developing and commercializing
new chemical entities designed to alleviate pain and pruritus by
selectively targeting peripheral kappa opioid receptors. Cara is
developing a novel and proprietary class of product candidates, led
by CR845, that target the body's peripheral nervous system. CR845
has demonstrated initial efficacy in patients with
moderate-to-severe pain, without inducing many of the undesirable
side effects typically associated with currently available pain
therapeutics. In patients with moderate-to-severe CKD-associated
pruritus, CR845 has demonstrated its potential to reduce itch and
improve quality of life.
Forward-looking Statements
Statements contained in this press release
regarding matters that are not historical facts are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Examples of these
forward-looking statements include statements concerning the future
development of the Company’s product candidates, including the
potential of CR845 to address medical needs in a range of pain and
pruritic conditions, and the ability to drive shareholder value.
Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Risks are described
more fully in Cara's filings with the Securities and Exchange
Commission, including the "Risk Factors" section of Cara's Annual
Report on Form 10-K for the year ended December 31,
2016 and its other documents subsequently filed with or
furnished to the Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Except to the extent
required by law, Cara undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com
INVESTOR CONTACT:
Michael Schaffzin
Stern Investor Relations, Inc.
212-362-1200
michael@sternir.com
Curis (NASDAQ:CRIS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Curis (NASDAQ:CRIS)
Historical Stock Chart
From Apr 2023 to Apr 2024